Open an account

Eloxx Pharmaceuticals

ELOX · OTC

$13.22+$0.72 (+5.76%)TodayMarket closed ·
Prev close $12.50

About ELOX

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Employees
10
Headquarters
Watertown, Massachusetts
Listed
Nov 23, 2012
Sector
Health Care
Industry
Pharmaceuticals
Website
eloxxpharma.com

ELOX key statistics

Market cap
53.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
24.56K
Volume
19.00K
Open price
$12.86
High today
$13.77
Low today
$12.86
52 Week high
$23.40
52 Week low
$0.00

Eloxx Pharmaceuticals (ELOX) at a glance

As of Oct 20, 2026, Eloxx Pharmaceuticals (ELOX) shares are priced at $13.22, giving the company a market cap of 53.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.86 and $13.77. The current price is 2.8% above the day's low and 4.0% below its high.

Volume so far is 19.00K shares, below the average of 24.56K shares a day.

Over the past year Eloxx Pharmaceuticals has ranged from $0.00 to $23.40, and now sits 56% of the way up that range.

Eloxx Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY23 it reported -$14.41 per share against an estimate of -$22.10.

The average analyst price target is $39.01, 195.1% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $39.01
Low
$32.32
Now
$13.22
High
$45.15

ELOX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 19.4% on average.

  1. Q4 FY21: reported -$61.60 per share against an estimate of -$53.86
  2. Q1 FY22: reported -$57.20 per share against an estimate of -$41.51
  3. Q2 FY22: reported -$52.80 per share against an estimate of -$46.37
  4. Q3 FY22: reported -$39.60 per share against an estimate of -$49.37
  5. Q4 FY22: reported -$32.12 per share against an estimate of -$33.32
  6. Q1 FY23: reported -$31.68 per share against an estimate of -$28.61
  7. Q2 FY23: reported -$21.56 per share against an estimate of -$17.28
  8. Q3 FY23: reported -$14.41 per share against an estimate of -$22.10

ELOX news

  • Press releasePRNewswire

    Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

  • Press releasePRNewswire

    Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

  • Press releasePRNewswire

    Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

  • Press releasePRNewswire

    Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Similar companies

Companies in the same industry as Eloxx Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.